We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Rosetta Genomics Receives New York State Clinical Laboratory Permit for Its microRNA Diagnostic Tests
News

Rosetta Genomics Receives New York State Clinical Laboratory Permit for Its microRNA Diagnostic Tests

Rosetta Genomics Receives New York State Clinical Laboratory Permit for Its microRNA Diagnostic Tests
News

Rosetta Genomics Receives New York State Clinical Laboratory Permit for Its microRNA Diagnostic Tests

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Rosetta Genomics Receives New York State Clinical Laboratory Permit for Its microRNA Diagnostic Tests"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

The permit will enable patients and physicians residing in the State of New York to gain access to the Company's miRview® mets, miRview® squamous, and miRview® meso tests. The Company is now working to gain NYS DOH approval for the first of its second generation tests -- miRview® mets2.

"We are pleased that these microRNA-based diagnostic products are now available to residents of all 50 U.S. states including New York State. Receipt of this permit confirms that Rosetta's CAP-accredited, CLIA-certified laboratory meets the strict requirements of New York State for quality-controlled, accurate and reliable clinical laboratory services," noted Kenneth A. Berlin, President and CEO of Rosetta Genomics. "Rosetta Genomics has made considerable investment in the development of our proprietary microRNA technology platform, and today we have a robust portfolio of diagnostic tests on the market, nearing commercial launch and in development. We look forward to providing the benefits of these powerful diagnostic products to a growing number of clinicians and patients."

Advertisement